Mumbai: Danish drugmaker Novo Nordisk has tied up with Indian pharma company Emcure Pharma to distribute and market a second brand of its diabetes and weight-loss injection semaglutide in a bid to widen its reach in the country using the Pune-based company's distribution channel and field force.
The semaglutide brand, to be exclusively distributed and commercialised by Emcure for weight loss in India, will be called Poviztra, and will be available in all the five dosage strengths as Novo Nordisk's own brand Wegovy.
In June, Novo Nordisk launched Wegovy (semaglutide) injections in five dosing strengths (0.25, 0.5, 1, 1.7 and 2.4 mg).
However, the company has not yet disclosed pricing details for Poviztra.
Wegovy is currently priced between ₹17,345 and ₹26,050 across dosages in India. It is prescribed for long-term chronic weight management and reduction in risk of major adverse cardiovascular events (MACE). In clinical trials, one in three participants on Wegovy experienced weight loss of over 20%.
"We realise that there is a significant need to go beyond the current set of population that can access Wegovy. The need for reaching a new set of population, geographies and territories is where this partnership comes into play," said Jay Thyagarajan, senior vice president, region APAC, Novo Nordisk.
Vikrant Shrotriya, managing director, Novo Nordisk India, said: "We are embarking with Emcure to become a very strong brand across India both because of science and also because of commercial sense that they bring to the table with their presence in multiple therapeutic areas".
The semaglutide brand, to be exclusively distributed and commercialised by Emcure for weight loss in India, will be called Poviztra, and will be available in all the five dosage strengths as Novo Nordisk's own brand Wegovy.
In June, Novo Nordisk launched Wegovy (semaglutide) injections in five dosing strengths (0.25, 0.5, 1, 1.7 and 2.4 mg).
However, the company has not yet disclosed pricing details for Poviztra.
Wegovy is currently priced between ₹17,345 and ₹26,050 across dosages in India. It is prescribed for long-term chronic weight management and reduction in risk of major adverse cardiovascular events (MACE). In clinical trials, one in three participants on Wegovy experienced weight loss of over 20%.
"We realise that there is a significant need to go beyond the current set of population that can access Wegovy. The need for reaching a new set of population, geographies and territories is where this partnership comes into play," said Jay Thyagarajan, senior vice president, region APAC, Novo Nordisk.
Vikrant Shrotriya, managing director, Novo Nordisk India, said: "We are embarking with Emcure to become a very strong brand across India both because of science and also because of commercial sense that they bring to the table with their presence in multiple therapeutic areas".
